{"title":"Długoterminowa skuteczność azacytydyny u chorej z ostrą białaczką szpikową na podłożu zmian dysplastycznych","authors":"M. Wójtowicz","doi":"10.5603/hem.2019.0004","DOIUrl":null,"url":null,"abstract":"Azacitidine is a hypomethylating agent, commonly used in treatment of acute myeloid leukemia with 20–30% bone marrow blasts. We present a case of a long-term efficacy of this drug used in the patient for 36 months.","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"15 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/hem.2019.0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Długoterminowa skuteczność azacytydyny u chorej z ostrą białaczką szpikową na podłożu zmian dysplastycznych
Azacitidine is a hypomethylating agent, commonly used in treatment of acute myeloid leukemia with 20–30% bone marrow blasts. We present a case of a long-term efficacy of this drug used in the patient for 36 months.
期刊介绍:
Hematology is the quarterly under auspices of the Institute of Hematology and Transfusion Medicine. The journal is addressed to hematologists, oncologists and also internists. It contains the overview/review articles, case reports, essays, including reports from the scientific and educational conferences as well as test questions on hematology. Journal of the Institute of Hematology and Transfusiology.